Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Drug Farm advances first potential therapy for rare ROSAH syndrome

Drug Farm advances first potential therapy for rare ROSAH syndrome

New Capabilities

A $55 million round pushes an oral ALPK1 inhibitor toward a late-stage trial for a genetic disease with no approved treatment

July 13th, 2026: Drug Farm raises $55 million

Overview

A few dozen families worldwide carry a gene mutation that slowly steals their sight and floods their bodies with inflammation. On July 13, 2026, Drug Farm announced it raised $55 million to push its candidate for that disease, ROSAH syndrome, into a Phase 3 trial.

DF-003 blocks a protein called ALPK1 that the mutation leaves stuck in the on position. The FDA has given it four designations, including Fast Track and Orphan Drug status, to speed it through review. In a small early trial, all six treated patients improved on at least one measure.

Why it matters

The first drug aimed at the cause of ROSAH syndrome is one trial away from possible approval, offering treatment where none exists today.

Questions about this story

No questions yet — be the first to ask.

Play on this story Voices Debate Predict Higher or Lower Timeline Connections

Key Indicators

$55M
Series D raised
Funds a late-stage trial for DF-003 and a second immune-modulating drug.
6 of 6
Patients improved in Phase 1b
Every treated patient improved on at least one clinical measure.
0
Approved ROSAH therapies
No drug currently treats the underlying disease.
Phase 3
Next trial stage
DF-003 is moving from early testing toward a pivotal study.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 3 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Henri Lichenstein
Henri Lichenstein
Leading the company through late-stage development and the Series D raise
 Zhijian James Chen
Zhijian James Chen
Advising the ALPK1 programs

Organizations Involved

Drug Farm
Drug Farm
Biotechnology company
Developer of DF-003 and DF-006

A clinical-stage biotech, with US and Shanghai operations, building drugs that tune the innate immune system.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal agency
Regulator reviewing DF-003's path to market

The agency that decides whether DF-003 can be sold in the United States and how much evidence that requires.
National Institutes of Health
National Institutes of Health
Federal Agency
Research partner for DF-003 ROSAH development

The federal biomedical research agency that signed an agreement with Drug Farm in December 2024 to co-develop a precision treatment for ROSAH syndrome.

Timeline

January 2024 July 2026

8 events Latest: July 13th, 2026 · 1 month ago
Tap a bar to jump to that date

  1. Drug Farm raises $55 million

    Latest Funding

    A Series D round funds the DF-003 Phase 3 trial and a second drug, DF-006, for hepatitis B and liver cancer.

  2. Early data shows patients improving

    Clinical

    At the ARVO 2026 meeting, Drug Farm reports all six treated patients improved on at least one measure, with no serious side effects.

  3. DF-003 wins orphan drug designation

    Regulatory

    The FDA grants DF-003 orphan status, adding development incentives for the rare disease.

  4. FDA opens flexible evidence path

    Regulatory

    The FDA accepts DF-003 into its Rare Disease Evidence Principles process, which tailors data requirements to very small patient groups.

  5. DF-003 earns FDA Fast Track designation

    Regulatory

    The FDA grants Fast Track status to DF-003, allowing more frequent agency interactions and eligibility for rolling review as Drug Farm moves toward a pivotal trial.

  6. Drug Farm and NIH sign ROSAH research agreement

    Partnership

    Drug Farm signs an agreement with the National Institutes of Health to co-develop a precision treatment for ROSAH syndrome, adding federal research capacity to the program.

  7. Phase 1b trial opens for ROSAH patients

    Clinical

    Drug Farm begins testing oral DF-003 in people with ROSAH syndrome after FDA clearance.

  8. FDA grants Rare Pediatric Disease designation

    Regulatory

    The FDA designates DF-003 for Rare Pediatric Disease status, making Drug Farm eligible for a Priority Review Voucher upon approval — a transferable asset worth tens of millions of dollars.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

March 2007

Soliris approved for PNH (2007)

The FDA approved Alexion's Soliris for paroxysmal nocturnal hemoglobinuria, a blood disorder affecting a few thousand US patients. It was the first drug to treat the disease. Alexion priced it near $400,000 a year.

Then

Patients gained a treatment that cut life-threatening blood clots and transfusion needs.

Now

The drug became a multibillion-dollar franchise and set a template for building a business around one ultra-rare disease.

Why this matters now

It shows how a first-in-class drug for a tiny population can reach patients and pay off, the path Drug Farm is now attempting for ROSAH.

January 2012

Kalydeco approved for cystic fibrosis (2012)

The FDA approved Vertex's Kalydeco, the first drug to treat the root genetic cause of cystic fibrosis rather than its symptoms. It worked for a small subset of patients with a specific mutation, roughly 4% of cases.

Then

Patients with the target mutation saw major gains in lung function.

Now

It proved that fixing a specific broken protein could transform a genetic disease, opening a wave of precision therapies.

Why this matters now

DF-003 also targets a single disease-causing mutation, aiming to correct the mechanism instead of managing symptoms.

December 2017

Luxturna approved for inherited blindness (2017)

The FDA approved Spark Therapeutics' Luxturna, the first gene therapy for an inherited retinal disease. It treated patients losing vision from mutations in the RPE65 gene, a group numbering in the low thousands.

Then

Treated patients regained meaningful vision, some navigating in dim light for the first time.

Now

It established that regulators would approve therapies for rare, vision-threatening genetic disorders on small trials.

Why this matters now

ROSAH also threatens sight through a genetic defect, and DF-003 is being judged, like Luxturna, on data from very few patients.

Sources

(9)
+4
Fierce Biotech BioWorld Business Wire PharmiWeb Nature Communications Business Wire Business Wire Business Wire Business Wire